Amphion Innovations plc
Directors Receive Shares in Lieu of Fees
London and New York, 3 October 2012- Amphion Innovations plc (the “Company”) (LSE: AMP), the developer of medical and technology businesses, announces that the Company has today issued 226,083 ordinary shares, representing 0.17% of the enlarged issued share capital, to certain of its Board members as their directors’ fees for the third quarter of 2012, priced at 2.675 pence, being the average of the closing mid-market price for the five days leading up to the market close on 28 September 2012. Following this issue, the directors’ shareholdings in the Company are as follows:
|R. James Macaleer||176,083||23,978,945||17.684%|
Director, Anthony Henfrey waived his fees for the third quarter of 2012.
Admission of the 226,083 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 8 October 2012. Following this allotment the total issued share capital of the Company will increase to 135,600,250 ordinary shares with each share holding one voting right.
For further information please contact
+1 212 210 6224
+44 (0)20 7930 0777
Seymour Pierce Limited, Nominated Advisor
Mark Percy (Corporate Financing)
David Banks (Corporate Broking)
+44 (0)20 7107 8000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com